Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 12/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990436 | 1.00 | BAZ2B (0.49) | BAZ2BLMNAMAPTCFTRCTSK | |
| SCHEMBL1988307 | 0.90 | LMNA (0.48) | BAZ2BLMNAMAPTCFTRCTSK | |
| SCHEMBL1988306 | 0.90 | LMNA (0.48) | BAZ2BLMNAMAPTCFTRCTSK | |
| SCHEMBL1986128 | 0.89 | KMT2A (0.46) | BAZ2BLMNAMAPTCFTRCTSK | |
| SCHEMBL1986126 | 0.89 | KMT2A (0.46) | BAZ2BLMNAMAPTCFTRCTSK | |
| SCHEMBL1992066 | 0.85 | CHRNA7 (0.44) | CFTR | |
| SCHEMBL1992069 | 0.85 | CHRNA7 (0.44) | CFTR | |
| SCHEMBL1987946 | 0.77 | TAAR1 (0.47) | TAAR1 | |
| SCHEMBL1987945 | 0.77 | TAAR1 (0.47) | TAAR1 | |
| SCHEMBL1989220 | 0.75 | PADI4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809532-B2 | Aza-ring fused indole and indoline derivatives | ABBVIE INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-20110152308-A1 | AZA-RING FUSED INDOLE AND INDOLINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-8809532-B2 | Aza-ring fused indole and indoline derivatives | ABBVIE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110152308-A1 | AZA-RING FUSED INDOLE AND INDOLINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152308-A1 | AZA-RING FUSED INDOLE AND INDOLINE DERIVATIVES | INMT, IDO1, IDO2 | BAZ2B 408/4885LMNA 2106/4885MAPT 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.